MPO and breast cancer: Although the CD15+ activated neutrophils were more frequent in the primary BC patient cohort investigated, only CD15+MPO− blasts had a negative impact on prognosis, similar to mouse studies (Andzinski et al, 2016), and were associated with the MDSC marker S100A9.